Buspirone Treatment of Iatrogenic Dyskinesias in Advanced Parkinson' Disease

NCT ID: NCT02617017

Last Updated: 2023-04-12

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 99 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2016-06-17
• Study Completion Date: 2023-03-23

Brief Summary

Parkinson's disease (PD) is one of the most common neurodegenerative diseases, with a higher prevalence in the elderly. Levodopa induced dyskinesias (LID) are a major motor complications that impair quality of life for patients with PD. The mechanisms of these dyskinesias remain unclear, but several hypotheses have been put forward: non continuous, pulsatile stimulation of dopaminergic receptors, or alterations of other neurotransmitters within the motor striatum such as glutamate and serotonin.

Few strategies are now available to treat severe LID:

• Medications: reduction of dopaminergic treatment, addition of amantadine,
• Functional neurosurgery. The purpose of this study is to investigate the efficacy of buspirone in PD patients suffering from dyskinesias. The role of serotonin in the occurrence of LID was recently demonstrated in transplant PD patients and a test double-blind, single dose was achieved. Following administration of 10 mg oral buspirone, a 5HT1A agonist, LID were clearly improved. A antidyskinetic effect of buspirone had already been reported in 1991 and 1994, but identification of buspirone as a serotonin receptor agonist has been reported more recently.

This trial is aimed at (1) validate the serotoninergic hypothesis of hyperkinetic levodopa induced dyskinesias (LID) in Pakinson's disease patients, (2) evaluate, in a phase 3 trial, the motor efficacy of buspirone to improve LID vs placebo, (3) look at a possible dose/effect relationship and (4) check the hypothesis of a better therapeutic ratio using the association of buspirone and amantadine instead than a single drug.

Conditions

Parkinson

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

Buspirone

Group Type: EXPERIMENTAL

Buspirone

Intervention Type: DRUG

Capsules of buspirone will be administered orally once a day for 2 weeks (10mg, morning), BID for 2 further weeks (20 mg, morning and evening), TID between weeks 5 and 12 (third intake at noon)

Placebo

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Capsules of placebo will be administered orally once a day for 2 weeks (10mg, morning), BID for 2 further weeks (20 mg, morning and evening), TID between weeks 5 and 12 (third intake at noon)

Interventions

Buspirone

Capsules of buspirone will be administered orally once a day for 2 weeks (10mg, morning), BID for 2 further weeks (20 mg, morning and evening), TID between weeks 5 and 12 (third intake at noon)

Intervention Type: DRUG

Placebo

Capsules of placebo will be administered orally once a day for 2 weeks (10mg, morning), BID for 2 further weeks (20 mg, morning and evening), TID between weeks 5 and 12 (third intake at noon)

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• The subject is an out-patient between 35 year and 80 years of age
• Diagnosis of idiopathic Parkinson's disease according to the UK Parkinson's Disease Society Brain Bank Clinical Diagnosis Criteria
• Dyskinesias are present more than 25% of the waking day according to item 4-1 of MDS-UPDRS
• Dyskinesias are at least moderately disabling item 4-2 of MDS-UPDRS replaced by Dyskinesias are at least slightly disabling item 4-2 of MDS-UPDRS (amendment n°2)
• The subject is able to identify dyskinesia, ON and OFF, and apply to his/her own state
• Stable dose of anti-Parkinsonian drugs for at least 4 weeks up to the screening
• The subject is considered as being optimally treated at the time of inclusion
• Written and signed informed consent to participate in the study
• Maximal Hoehn and Yahr staging : III in "ON" phases, IV in "OFF"
• Active affiliation to social security
• Menopausal or under contraception for woman

Exclusion Criteria

• Female subjects : pregnant or lactating
• Atypical parkinsonian syndrome
• Weight less than 40 Kgs
• Mini-Mental State Examination (MMSE) less than 24
• The subject is participating in another clinical study within the past 12 weeks
• Planned participation in another therapeutic clinical study
• Previous treatment with buspirone, less than 6 months before Week 0
• Known allergy to buspirone
• Known lactose intolerance
• Clinically significant illness that might interfere with the study
• Dementia or other psychiatric illness
• Drug or alcohol abuse replaced by Substance use disorder (alcohol i.e. > 3 drinks per day for men and > 2 drinks per day for women,drug, medicinal product) (amendment n°1)
• Legal incapacity or limited legal capacity
• Deep brain stimulation performed less than 12 months before protocol initiation, or unstable parameters of stimulation 4 weeks before week 0
• Severe renal and / or hepatic impairment
• History of seizures or epilepsy

• Minimum Eligible Age: 35 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Assistance Publique - Hôpitaux de Paris

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Philippe Rémy, PhD

Role: PRINCIPAL_INVESTIGATOR

Assistance Publique - Hôpitaux de Paris

Locations

Henri Mondor Hospital

Créteil, , France

Countries

France

References

McFarthing K, Prakash N, Simuni T. CLINICAL TRIAL HIGHLIGHTS - DYSKINESIA. J Parkinsons Dis. 2019;9(3):449-465. doi: 10.3233/JPD-199002. No abstract available.

Reference Type: DERIVED

PMID: 31356217 (View on PubMed)

Other Identifiers

2015-002332-41

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

P130909

Identifier Type: -

Identifier Source: org_study_id